FDA Approves First mRNA Flu Vaccine for Adults Over 50, Enhancing Seasonal Flu Protection
The U.S. Food and Drug Administration (FDA) has approved the first mRNA flu vaccine, mFlusiva® produced by Moderna, for adults aged 50 and older. This marks a significant advancement in influenza vaccination technology. For the 2026-27 flu season, all U.S.-approved vaccine formulas are trivalent, offering protection against three viral strains: H1N1, H3N2, and B/Victoria lineage virus. While approximately 75% of the U.S. flu vaccine supply remains egg-based, with viruses grown in fertilized eggs, other options include cell-based vaccines (viruses grown in mammal cells) and recombinant vaccines (using genetic engineering). In addition to the new mRNA vaccine, there are three specially formulated vaccines available for adults over 65, and a nasal spray option (Flumist®) for healthy individuals aged 2 to 49 who prefer a non-needle alternative. The CDC recommends vaccination for everyone over six months of age, with specific medical or personal exceptions.